Short Summary
Fluidmaster successfully defended its toilet‑fill valve patent in an IPR Director Review, with the PTAB denying Danco’s request to overturn the Board’s claim construction and unpatentability findings.
Detailed Summary
In IPR2024‑00635, the PTAB had held that claims 8 and 12 of Fluidmaster’s U.S. Patent No. 10,934,698 were unpatentable because the term “overflow tube” was correctly construed as a functional reference point rather than a separate structural limitation. Danco sought Director Review, arguing the opposite construction and asserting that the prior art did not disclose the claimed features. Fluidmaster countered that the Board’s construction aligns with Federal Circuit precedent and that the prior‑art references Guoxin and Ho satisfy the limitations under the proper interpretation. The Director Review was denied, leaving the Board’s findings intact.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Fluidmaster, Inc. vs Danco, Inc. et al. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Intel CorporationvsAdvanced Cluster Systems, Inc.
The USPTO denied Intel’s request for rehearing of the Director’s discretionary denial and the denial of institution in IPR2025‑00795, leaving the original decision intact.
Olympus Corporation et al.vsOptimum Imaging Technologies LLC
Olympus and Optimum Imaging have reached a settlement-in-principle in their imaging patent dispute, seeking a stay of court deadlines and planning to dismiss the case.
Samsung Electronics Co., Ltd. et al.vsWilus Institute of Standards and Technology Inc.
Wilus sought leave to address recent director‑review decisions and submit new evidence in five IPRs, but the Director denied the request, citing policy against inconsistent claim constructions and statutory timing constraints.
Curio Bioscience, Inc.vsPrognosys Biosciences Inc. et al.
The PTAB denied Curio Bioscience's IPR challenge against Prognosys and 10X Genomics, finding that the asserted claims were not obvious or anticipated by the prior art. The Board specifically rejected arguments linking Cantor to spatial analysis in tissue sections.
Samsung Electronics Co., Ltd. et al.vsHermes IP Management LLC
Samsung and Hermes IP reached a settlement and jointly moved to terminate the inter partes review of U.S. Patent 8,855,720 covering a mobile device user interface.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.